$35.59
0.08% yesterday
Nasdaq, Jun 13, 10:11 pm CET
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Ionis Pharmaceuticals, Inc. Stock price

$35.59
+3.06 9.41% 1M
-1.02 2.79% 6M
+0.63 1.80% YTD
-5.53 13.45% 1Y
-21.62 37.79% 5Y
-26.86 43.01% 10Y
+31.69 812.56% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.03 0.08%
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Key metrics

Market capitalization $5.66b
Enterprise Value $4.77b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.65
P/S ratio (TTM) P/S ratio 7.90
P/B ratio (TTM) P/B ratio 11.90
Revenue growth (TTM) Revenue growth -7.64%
Revenue (TTM) Revenue $717.25m
EBIT (operating result TTM) EBIT $-472.43m
Free Cash Flow (TTM) Free Cash Flow $-555.15m
Cash position $2.15b
EPS (TTM) EPS $-2.88
P/E forward negative
P/S forward 7.66
EV/Sales forward 6.45
Short interest 12.37%
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

18x Buy
67%
8x Hold
30%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
30%
Sell
4%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
717 717
8% 8%
100%
- Direct Costs 11 11
6% 6%
1%
707 707
8% 8%
99%
- Selling and Administrative Expenses 291 291
22% 22%
41%
- Research and Development Expense 888 888
3% 3%
124%
-451 -451
24% 24%
-63%
- Depreciation and Amortization 22 22
42% 42%
3%
EBIT (Operating Income) EBIT -472 -472
24% 24%
-66%
Net Profit -458 -458
19% 19%
-64%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
2 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. “Richard has made tremendous contributions to Ionis over his 30-year tenure...
Neutral
Business Wire
3 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to signifi...
Neutral
Business Wire
26 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 1,069
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today